Large Michigan Hospital Study Proves HCQ as COVID-19 Cure

Written by John O'Sullivan on August 3, 2020. Posted in Current News

The International Journal of Infectious Diseases (IJID) publishes a persuasive medical study performed inside a busy teaching hospital. Over 2,500 patients were involved. The authors proved that hydroxychloroquine gave a “significant reduction” in hospital deaths from the disease.

The growing anecdotal evidence from frontline doctors is demonstrating positive evidence for using the ‘Trump Cure’ in the battle against the COVID-19 pandemic.

This new study offers an important clinical validation proving efficacy of hydroxycholoroquine (HCQ) in treating COVID-19. See: ‘Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19’ (DOI:https://doi.org/10.1016/j.ijid.2020.06.099)

The authors tell us:

“Hydroxychloroquine, an antimalarial and immunomodulatory agent and a safer analogue of chloroquine, has demonstrated antiviral activity against SARS-CoV-2 (Wang et al., 2020a, Liu et al., 2020, Yao et al., 2020, WHO, 2017).

An in vitro study demonstrated synergistic activity of the combination of hydroxychloroquine and azithromycin against SARS-CoV-2 (Andreani et al., 2020). A small non-randomized, open-label trial from France reported higher frequency of SARS-CoV-2 clearance after six days of treatment with hydroxychloroquine alone or hydroxychloroquine in combination with azithromycin versus untreated control group (70% vs 12.5%; P < 0.001) (Gautret et al., 2020a). Other early studies of hydroxychloroquine have reported conflicting results (Gao et al., 2020, Gautret et al., 2020b, Chen et al., 2020a, Tang et al., 2020, Chen et al., 2020b, Yu et al., 2020, Geleris et al., 2020, Rosenberg et al., 2020, Magagnoli et al., 2020, Million et al., 2020).”

The study carefully tracked patients at the Henry Ford Health System (HFHS) in Southeast Michigan on the HCQ treatment. Overall, 2,541 consecutive patients were included in the analyses with a median age of 64 years (IQR: 53–76 years). The primary endpoint was in-patient hospital mortality in each treatment group. All deaths were reviewed in detail by the study team. The authors reported:

“The results of this study demonstrate that in a strictly monitored protocol-driven in-hospital setting, treatment with hydroxychloroquine alone and hydroxychloroquine + azithromycin was associated with a significant reduction in mortality among patients hospitalized with COVID-19.”

Read and download the PDF of the full paper at https://www.ijidonline.com/article/S1201-9712(20)30534-8/fulltext

About the author: John O’Sullivan John is CEO and co-founder (with Dr Tim Ball) of Principia Scientific International (PSI).  John is a seasoned science writer and legal analyst who assisted Dr Ball in defeating world leading climate expert, Michael ‘hockey stick’ Mann in the ‘science trial of the century‘. O’Sullivan is credited as the visionary who formed the original ‘Slayers’ group of scientists in 2010 who then collaborated in creating the world’s first full-volume debunk of the greenhouse gas theory plus their new follow-up book.

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Please DONATE TODAY To Help Our Non-Profit Mission To Defend The Scientific Method.

Trackback from your site.